Influenza Vaccine Effectiveness in European Primary Care Pediatric Practices: 2022–2024
Authors:
- 6 April 2026
- journal article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 157 (5)
Abstract
OBJECTIVES: To estimate influenza vaccine effectiveness (VE) in the pediatric population (<18 years) attending primary care in the European Union and European Economic Area in 2022/2023 and 2023/2024. METHODS: General practitioners swabbed and interviewed patients with acute respiratory tract infection. We conducted a test-negative case-control study and used logistic regression to estimate VE against any influenza and specific (sub)types, overall and by age group, and within the vaccine recommendation target group. RESULTS: Among 10 368 children in 2022/23, 3286 (32%) tested polymerase chain reaction-positive for influenza virus; among 9270 children in 2023/24, 1567 (17%) tested positive. Influenza A(H3N2) and B predominated in 2022/23, and influenza A(H1N1)pdm09 in 2023/24. Among the test-negative controls, 17% were part of the vaccine recommendation target group in 2022/23 and 38% in 2023/24. In 2022/23, overall VE against any influenza was 68% (95% CI: 59–76); 57% (95% CI: 26–76) against influenza A(H1N1)pdm09; 54% (95% CI: 33–69) against influenza A(H3N2); 83% (95% CI: 74–90) against influenza B. In 2023/24, overall VE against any influenza was 71% (95% CI: 62–78); 75% (95% CI: 64–83) against influenza A(H1N1)pdm09; 40% (95% CI: 4–64) against influenza A(H3N2); and 92% (95% CI: 63–100) against influenza B. All VE estimates varied by age and vaccine recommendation target group. CONCLUSIONS: In 2022/23 and 2023/24, more than two-thirds of vaccinated children were protected against primary care-attended influenza infection in Europe. Monitoring VE in children can help inform influenza immunization programs.Keywords
This publication has 19 references indexed in Scilit:
- Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United KingdomInfluenza and Other Respiratory Viruses, 2024
- End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great BritainInfluenza and Other Respiratory Viruses, 2024
- Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre studyInfluenza and Other Respiratory Viruses, 2024
- Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: A systematic review and meta-analysisVaccine, 2018
- Immune responses after live attenuated influenza vaccinationHuman Vaccines & Immunotherapeutics, 2018
- Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine EffectivenessAmerican Journal of Epidemiology, 2016
- Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studiesThe Lancet Infectious Diseases, 2016
- The healthcare and societal burden associated with influenza in vaccinated and unvaccinated European and Israeli childrenEuropean Journal of Clinical Microbiology & Infectious Diseases, 2013
- The test-negative design for estimating influenza vaccine effectivenessVaccine, 2013
- A simulation study of the number of events per variable in logistic regression analysisJournal of Clinical Epidemiology, 1996